Dermapharm Holding SECHIX:DMPD 80 Return-on-Tangible-Asset is 15.51% as of Mar. 2026, which is 1% below its 10-year median of 15.62. GuruFocus rates CHIX:DMPD with a GF Score™ of 80/100 and a GF Value™ of €38.51. The stock has 9 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Dermapharm Holding SE ranks better than 86.07% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Dermapharm Holding SE's annualizedNet Income for the quarter that ended in Mar. 2026 was €181 Mil. Dermapharm Holding SE's average total tangible assets for the quarter that ended in Mar. 2026 was €1,166 Mil. Therefore, Dermapharm Holding SE's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 15.51%.
The historical rank and industry rank for Dermapharm Holding SE's Return-on-Tangible-Asset or its related term are showing as below:
CHIX:DMPd'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 6.66 Med: 15.62 Max: 35.25
Current: 13.17
During the past 13 years, Dermapharm Holding SE's highest Return-on-Tangible-Asset was 35.25%. The lowest was 6.66%. And the median was 15.62%.
CHIX:DMPd's Return-on-Tangible-Asset is ranked better than 86.07% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 3.15
vs CHIX:DMPd: 13.17
Dermapharm Holding SE (CHIX:DMPd) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Dermapharm Holding SE Return-on-Tangible-Asset Related Terms
Dermapharm Holding SE Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Dermapharm Holding SE's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dermapharm Holding SE Return-on-Tangible-Asset Chart
CHIX:DMPD vs ZTS, UTHR, VTRS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Dermapharm Holding SE's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dermapharm Holding SE Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dermapharm Holding SE's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Dermapharm Holding SE's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 15.51% mean?
Dermapharm Holding SE (CHIX:DMPD) has a Return-on-Tangible-Asset of 15.51% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Dermapharm Holding SE and its competitors. This is near median its historical median of 15.62. Over the past decade, Dermapharm Holding SE's Return-on-Tangible-Asset has ranged from 6.66 to 35.25. According to the industry distribution chart, Dermapharm Holding SE ranks #140 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 13.9%.
Is Dermapharm Holding SE's Return-on-Tangible-Asset too high?
Dermapharm Holding SE's current Return-on-Tangible-Asset of 15.51% is near median its 10-year median of 15.62. Over the past 10 years, this metric has ranged from a low of 6.66 to a high of 35.25. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.15. Dermapharm Holding SE's value of 15.51% is 392.4% above this industry median. Based on the distribution chart, Dermapharm Holding SE ranks #140 out of 1005 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Dermapharm Holding SE has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Dermapharm Holding SE's Return-on-Tangible-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Dermapharm Holding SE ranks #140 out of 1005 companies for Return-on-Tangible-Asset. This places Dermapharm Holding SE in the top 14% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.15. Dermapharm Holding SE's value of 15.51% is 392.4% above this benchmark. Historically, Dermapharm Holding SE's own Return-on-Tangible-Asset has ranged from 6.66 to 35.25 over the past decade. While the company's 10-year median is 15.62 vs. the industry median of 3.15, Dermapharm Holding SE has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.15, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dermapharm Holding SE's current Return-on-Tangible-Asset of 15.51% is 392.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Dermapharm Holding SE and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dermapharm Holding SE's current Return-on-Tangible-Asset is 15.51%, which is near median its own 10-year median of 15.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dermapharm Holding SE stock overvalued right now?
Dermapharm Holding SE (CHIX:DMPD) has a current Return-on-Tangible-Asset of 15.51%. The stock's GF Value™ is €38.51, compared to a current price of €46.18 — trading 19.9% above its estimated fair value. The current Return-on-Tangible-Asset is 15.51%, which is near median its 10-year median of 15.62 and 392.4% above the Drug Manufacturers industry median of 3.15. Dermapharm Holding SE's overall GF Score™ is 80/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Dermapharm Holding SE (CHIX:DMPD), the current Return-on-Tangible-Asset is 15.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dermapharm Holding SE (CHIX:DMPD) Overvalued in 2026?
Based on GuruFocus' analysis, Dermapharm Holding SE stock appears to be overvalued.
The current stock price of €46.18 is trading 19.9% above its estimated GF Value™ of €38.51.
Key valuation signals for CHIX:DMPD:
Return-on-Tangible-Asset: 15.51% (near median its 10-year median of 15.62)
GF Value™: €38.51 vs. price of €46.18 (19.9% above fair value)
Industry Position: 392.4% above the Drug Manufacturers median (#140 of 1005)
No single metric tells the full story. See the CHIX:DMPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.
80GF Score
Get the complete analysis for CHIX:DMPD
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DMPD has been successfully added to your 
